natgillin/translations-raw huggingface dataset:
In a population pharmacokinetic analysis from 9 controlled clinical trials of 350 patients with asthma aged 4 to 77 years (174 patients 4 to 11 years of age) higher fluticasone propionate systemic exposure following treatment with salmeterol/fluticasone propionate inhalation powder 50/100 compared with fluticasone propionate inhalation powder 100 was seen.
V analizi populacijske farmakokinetike iz 9 kontroliranih kliničnih preskušanj pri 350 bolnikih z astmo, starih od 4 do 77 let (174 bolnikov od 4 do 11 let), so opazili večjo sistemsko izpostavljenost flutikazonpropionatu po zdravljenju s salmeterolom/flutikazonpropionatom 50/100 mikrogramov, v primerjavi s flutikazonpropionatom 100 mikrogramov.
Aerivio Spiromax should be administered with caution in patients with active or quiescent pulmonary tuberculosis and fungal, viral or other infections of the airway.
Zdravilo Aerivio Spiromax je treba uporabljati previdno pri bolnikih z aktivno ali mirujočo pljučno tuberkulozo ter pri glivičnih, virusnih ali drugih okužbah dihal.
Do not breathe through your inhaler.
Ne dihajte skozi inhalator.
Percentage of Patients Attaining *Well Controlled (WC) and **Totally Controlled (TC) Asthma over
Odstotek bolnikov, ki so dosegli *dobro nadzorovanost (DN) in **popolno nadzorovanost (PN) astme v 12 mesecih Salmeterol/FP
Physicians should remain vigilant for the possible development of pneumonia and other lower respiratory tract infections in patients with COPD as the clinical features of such infections and exacerbation frequently overlap.
Zdravniki morajo budno spremljati možnost razvoja pljučnice ali okužbe spodnjih dihal pri bolnikih s KOPB, saj se klinične lastnosti takih okužb in poslabšanje KOPB pogosto prekrivajo.
Potentially serious hypokalaemia may result from β2 agonist therapy.
Zdravljenje z agonisti β2 lahko povzroči resno hipokaliemijo.
D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE
D. POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO
This possibility of residual impairment should always be borne in mind in emergency and elective situations likely to produce stress, and appropriate corticosteroid treatment must be considered.
V nujnih primerih in v elektivnih okoliščinah, v katerih je verjeten stres, je vedno treba upoštevati možnost rezidualne okvare in poskrbeti za ustrezno zdravljenje s kortikosteroidi.
If you open and close the mouthpiece without taking an inhalation the dose indicator will still register it as a count.
Če ustnik odprete in zaprete brez inhaliranja, to kazalnik odmerka registrira in odšteje.
In an interaction study in healthy subjects with intranasal fluticasone propionate, ritonavir (a highly potent cytochrome P450 3A4 inhibitor) 100 mg twice daily increased the fluticasone propionate plasma concentrations several hundred fold, resulting in markedly reduced serum cortisol concentrations.
V študiji medsebojnega delovanja pri zdravih preiskovancih, ki so uporabljali flutikazonpropionat intranazalno, je ritonavir (zelo močan zaviralec citokroma P450 3A4) v odmerku 100 mg dvakrat na dan večstokrat zvišal koncentracijo flutikazonpropionata v plazmi, kar je povzročilo izrazito znižanje kortizola v serumu.
Peak Inspiratory Flow Rate through the Spiromax Device A randomised, open-label cross-over study was performed in children and adolescents with asthma (aged 417 years), adults with asthma (aged 18-45 years), adults with chronic obstructive pulmonary disease (COPD) (aged older than 55 years) and healthy volunteers (aged 18-45 years) to evaluate the peak inspiratory flow rate (PIFR) and other related inhalation parameters following inhalation from a Spiromax device (containing placebo) compared with inhalation from an already marketed multi-dose dry powder inhaler device (containing placebo).
Največja inspiratorna hitrost pretoka skozi pripomoček Spiromax Pri otrocih in mladostnikih z astmo (starih od 4 do 17 let), odraslih z astmo (starih od 18 do 45 let), odraslih s kronično obstruktivno pljučno boleznijo (KOPB) (starejših od 55 let) in zdravih prostovoljcih (starih od 18 do 45 let) so opravili randomizirano, odprto križno študijo za ocenitev največje inspiratorne hitrosti pretoka (PIFR, peak inspiratory flow rate) in drugih povezanih inhalacijskih parametrov po inhaliranju iz pripomočka Spiromax (s placebom) v primerjavi z inhaliranjem iz večodmernega pripomočka za inhaliranje s suhim praškom (s placebom), ki je na trgu.
COPD patients with a baseline (pre-bronchodilator) FEV1 <60% of predicted normal were randomised to double-blind medication.
Bolniki s KOPB z izhodiščno (pred bronhodilatatorjem) FEV1 < 60 % predvidene normalne vrednosti so bili randomizirani v skupine za dvojno slepo zdravljenje.
• Use within 3 months of removing from the foil wrapping.
• Uporabite v 3 mesecih od odstranitve ovoja iz folije.
In cases of both acute and chronic fluticasone propionate overdose Aerivio Spiromax therapy should be continued at a suitable dose for symptom control.
Pri akutnem in kroničnem prevelikem odmerjanju flutikazonpropionata je treba zdravljenje z zdravilom Aerivio Spiromax nadaljevati z ustreznim odmerkom za nadzorovanje simptomov.
Therapy should be down-titrated under physician supervision.
Zdravljenje je treba zmanjševati pod zdravniškim nadzorom.
Patients should be made aware that Aerivio Spiromax must be used daily for optimum benefit, even when asymptomatic.
Bolnikom je treba pojasniti, da morajo za najboljši učinek zdravilo Aerivio Spiromax uporabljati vsak dan, tudi kadar nimajo simptomov.
Patients should be advised to have their inhaler to be used for relief in an acute asthma attack available at all times.
Bolnikom naročite, naj imajo vedno pri sebi svoj inhalator, ki ga uporabljajo za olajšanje akutnega napada astme.
The average improvement over three years for salmeterol/fluticasone propionate compared with placebo was -3.1 units (95% CI: -4.1 to -2.1; p<0.001) and when compared with salmeterol was -2.2 units (p<0.001) and when compared with FP was -1.2 units (p=0.017).
Povprečno izboljšanje v treh letih za salmeterol/flutikazonpropionat v primerjavi s placebom je bilo -3,1 enote (95-odstotni IZ: -4,1 do -2,1; p < 0,001), v primerjavi s salmeterolom -2,2 enoti (p < 0,001) in v primerjavi s FP -1,2 enoti (p = 0,017).
If you feel more wheezy, your chest feels tight more often or you need to use more of your fast-acting ‘reliever' medicine, your chest condition may be getting worse and you could become seriously ill. You should continue to take Aerivio Spiromax but do not increase the number of puffs you take.
Če se vam zdi, da bolj piskajoče dihate, imate pogosteje občutek stiskanja v prsnem košu ali če pogosteje potrebujete hitrodelujoče 'olajševalno' zdravilo, se morda vaše stanje v prsnem košu slabša in lahko se zgodi, da resno zbolite.
The time on treatment for 50% of subjects to achieve a first individual well controlled week was 16 days for salmeterol/fluticasone propionate compared with 37 days for the ICS group.
Pri 50 % oseb je bil prvi posamezni teden z dobro nadzorovanostjo dosežen po 16 dneh zdravljenja s salmeterolom/flutikazonproprionatom v primerjavi s 37 dnevi zdravljenja z IKS.
The safety and efficacy of Aerivio Spiromax in children and adolescents aged less than 18 years of age has not been established.
Varnost in učinkovitost zdravila Aerivio Spiromax pri otrocih in mladostnikih, starih manj kot 18 let, nista bili dokazani.
The primary endpoint was reduction in all-cause mortality at 3 years for salmeterol/fluticasone
Primarni cilj študije je bil ugotoviti zmanjšanje umrljivosti zaradi vseh vzrokov po 3 letih uporabe salmeterola/flutikazonpropionata v primerjavi s placebom.
• Breathing difficulties or wheezing that gets worse straight after taking Aerivio Spiromax.
• Poslabšanje težav z dihanjem ali piskajočega dihanja takoj po uporabi zdravila Aerivio Spiromax.
Salmeterol/Fluticasone propionate - Asthma clinical trials A twelve month study (Gaining Optimal Asthma ControL, GOAL), in 3416 adult and adolescent patients with persistent asthma, compared the safety and efficacy of salmeterol/fluticasone propionate versus inhaled corticosteroid (fluticasone propionate) alone to determine whether the goals of asthma management were achievable.
Klinična preskušanja salmeterola/flutikazonpropionata pri bolnikih z astmo Dvanajstmesečna študija GOAL (Gaining Optimal Asthma ControL) pri 3.416 odraslih in mladostnikih s perzistentno astmo je primerjala varnost in učinkovitost salmeterola/flutikazonproprionata in samega inhalacijskega kortikosteroida (IKS) (flutikazonpropionata) za ugotovitev, ali je mogoče doseči cilje obvladanja astme.
See your doctor at once as you may need
Takoj obiščite zdravnika, saj morda potrebujete dodatno zdravljenje.
• Low potassium in your blood
• nizko raven kalija v krvi
To reduce the chance of side effects your doctor will prescribe the lowest dose of this combination of drugs to control your
Za zmanjšanje možnosti neželenih učinkov vam bo vaš zdravnik predpisal najmanjši odmerek te kombinacije zdravil za nadzorovanje vaše astme ali KOPB.
Pooled results across the 3 treatment levels *Well controlled asthma - less than or equal to 2 days with symptom score greater than 1 (symptom score 1 defined as ‘symptoms for one short period during the day'), SABA use on less than or equal to 2 days and less than or equal to 4 occasions/week, greater than or equal to 80% predicted morning peak expiratory flow, no night-time awakenings, no exacerbations and no side effects enforcing a change in therapy **Total control of asthma - no symptoms, no SABA use, greater than or equal to 80% predicted morning peak expiratory flow, no night-time awakenings, no exacerbations and no side effects enforcing a change in
KDAB - kratkodelujoči agonist receptorjev beta, BDP - beklometazondipropionat *Dobra nadzorovanost astme; 2 dni ali manj s seštevkom simptomov več kot 1 (seštevek simptomov 1 je opredeljen kot 'simptomi za eno kratko obdobje v dnevu'), uporaba KDAB 2 dni ali manj in ob 4 ali manj priložnostih/teden, 80 % ali več predvidene jutranje pljučne funkcije, brez prebujanj ponoči, brez poslabšanj in brez neželenih učinkov, zaradi katerih bi bilo treba zdravljenje spremeniti Popolna nadzorovanost astme: brez simptomov, brez uporabe KDAB, 80 % ali več predvidene jutranje pljučne funkcije, brez prebujanj ponoči, brez poslabšanj in brez neželenih učinkov, zaradi katerih bi bilo treba zdravljenje spremeniti.
However, Aerivio Spiromax should not be used to relieve an attack of breathlessness or wheezing.
Vendar pa zdravila Aerivio Spiromax ne smete uporabljati za lajšanje napadov zasoplosti in piskajočega dihanja.
Treatment with Aerivio Spiromax should not be stopped abruptly in patients with asthma due to risk of exacerbation.
Zdravljenja z zdravilom Aerivio Spiromax pri bolnikih z astmo se ne sme prekiniti nenadoma, ker obstaja nevarnost za poslabšanje.
The results of both studies showed that treatment with salmeterol/fluticasone propionate 50/250 resulted in a significantly lower annual rate of moderate/severe COPD exacerbations compared with salmeterol (SCO40043: 1.06 and 1.53 per subject per year, respectively, rate ratio of 0.70, 95% CI: 0.58 to 0.83, p<0.001; SCO100250: 1.10 and 1.59 per subject per year, respectively, rate ratio of 0.70, 95% CI: 0.58 to 0.83, p<0.001).
Izsledki obeh študij so pokazali, da je zdravljenje s salmeterolom/flutikazonpropionatom 50/250 povzročilo značilno nižjo letno število zmernih/hudih poslabšanj KOPB v primerjavi s salmeterolom (SCO40043: 1,06 oz. 1,53 na bolnika na leto, razmerje deležev 0,70; 95-odstotni IZ: 0,58 do 0,83, p < 0,001; SCO100250: 1,10 oz. 1.59 na bolnika na leto, razmerje deležev 0,70, 95-odstotni IZ: 0,58 do 0,83; p < 0,001).
The Spiromax device is a breath actuated, inspiratory flow-driven inhaler, which means that the active substances are delivered into the airways when the patient inhales through the mouthpiece.
Pripomoček Spiromax je inhalator, ki se aktivira pri vdihu in uporablja vdišni tok, kar pomeni, da se zdravilni učinkovini v dihala vneseta ob bolnikovem vdihu skozi ustnik.
Children received either salmeterol/fluticasone propionate (50/100 micrograms) or fluticasone propionate (100 micrograms) alone twice daily.
Otroci so prejeli bodisi samo salmeterol/flutikazonpropionat (50/100 mikrogramov) ali samo flutikazonpropionat (100 mikrogramov) dvakrat dnevno.
This can increase your risk of side effects with Aerivio Spiromax, including irregular heartbeats, or may make
To lahko poveča tveganje za neželene učinke z zdravilom Aerivio Spiromax, vključno z nerednim srčnim utripom, ali nekatere neželene učinke poslabša.
Aerivio Spiromax should be discontinued immediately, the patient assessed and alternative therapy instituted if necessary.
Uporabo zdravila Aerivio Spiromax je treba takoj prekiniti, bolnika pregledati in uvesti drugo zdravljenje, če je potrebno.
Patients were enrolled if ≥12 years of age, with asthma and if currently using asthma medication (but not a LABA).
Vključeni so bili bolniki z astmo, stari 12 ali več let, ki so trenutno uporabljali zdravila proti astmi (vendar ne dolgodelujočih agonistov beta 2).
- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist.
- bolniki, pri katerih so simptomi nadzorovani z velikim odmerkom inhalacijskega kortikosteroida in dolgodelujočim agonistom adrenergičnih receptorjev β2.
In a 12-week trial of children aged 4 to 11 years [n=257] treated with either salmeterol/fluticasone propionate 50/100 or salmeterol 50 micrograms + fluticasone propionate 100 micrograms both twice daily, both treatment arms experienced a 14% increase in peak expiratory flow rate as well as improvements in symptom score and rescue salbutamol use.
V 12-tedenskem preskušanju pri otrocih, starih od 4 do 11 let [n = 257], zdravljenih bodisi s salmeterolom/flutikazonpropionatom 50/100 bodisi s salmetrolom 50 mikrogramov + flutikazonproprionatom 100 mikrogramov, oboje dvakrat na dan, je bilo v obeh zdravljenih skupinah opaziti 14-odstotno povečanje predvidene pljučne funkcije, kot tudi izboljšanje izida glede simptomov in rešilne uporabe salbutamola.
Placebo-controlled clinical trials, over 6 and 12 months, have shown that regular use of salmeterol/fluticasone propionate 50/500 micrograms improves lung function and reduces breathlessness and
S placebom kontrolirani 6- in 12-mesečni klinični preskušanji sta pokazali, da redna uporaba salmeterola/flutikazonpropionata 50/500 mikrogramov izboljša delovanje pljuč, ublaži zasoplost in zmanjša uporabo zdravila za olajšanje.
Patients of black African or Afro-Caribbean ancestry should therefore be asked to continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen whilst using
Bolnikom črnega afriškega ali afrokaribskega porekla je treba zato naročiti, da zdravljenje nadaljujejo, vendar se posvetujejo z zdravnikom, če astme še naprej ne morejo nadzorovati ali če se med uporabo salmeterola/flutikazonpropionata pojavi poslabšanje.
Aerivio Spiromax is indicated for the symptomatic treatment of patients with COPD, with a FEV1 <60% predicted normal (pre-bronchodilator) and a history of repeated exacerbations, who have significant symptoms despite regular bronchodilator therapy.
Kronična obstruktivna pljučna bolezen (KOPB) Zdravilo Aerivio Spiromax je indicirano za simptomatsko zdravljenje bolnikov s KOPB s FEV1 < 60 % predvidene normalne vrednosti (pred bronhodilatatorjem) in anamnezo ponavljajočih se poslabšanj, ki imajo izrazite simptome kljub rednemu zdravljenju z bronhodilatatorjem.
In patients with asthma or COPD a lesser degree of systemic exposure to inhaled fluticasone propionate has been
Pri bolnikih z astmo ali KOPB so opažali manjšo stopnjo sistemske izpostavljenosti flutikazonpropionatu.
Aerivio Spiromax contains two medicines, salmeterol and fluticasone propionate:
Zdravilo Aerivio Spiromax vsebuje dve učinkovini, salmeterol in flutikazonpropionat:
Co-treatment with CYP3A inhibitors, including cobicistat-containing products, is expected to increase the risk of systemic side-effects.
Pri sočasnem zdravljenju z zaviralci encimov CYP3A, vključno z zdravili, ki vsebujejo kobicistat, se pričakuje povečano tveganje za sistemske neželene učinke.
Pneumonia-related events were reported for 55 (7%) subjects in the salmeterol/fluticasone propionate 50/250 micrograms twice daily group and 25 (3%) in the salmeterol group.
O neželenih učinkih, povezanih s pljučnico, so poročali za 55 (7 %) oseb v skupini s salmeterolom/flutikazonpropionatom 50/250 mikrogramov dvakrat na dan in 25 (3 %) v skupini s salmeterolom.
What you need to know before you use Aerivio Spiromax
Kaj morate vedeti, preden boste uporabili zdravilo Aerivio Spiromax
Prolonged treatment of patients with high doses of inhaled corticosteroids may result in adrenal suppression and acute adrenal crisis.
Dolgotrajno zdravljenje z velikimi odmerki inhalacijskih kortikosteroidov lahko zavre delovanje nadledvičnih žlez in povzroči akutno adrenalno krizo.
Key findings from SMART by inhaled steroid use at baseline: secondary endpoints Number of secondary endpoint
Ključne ugotovitve študije SMART pri uporabi inhalacijskega kortikosteroida v izhodišču: sekundarni
The only safety concerns for human use derived from animal studies of salmeterol and fluticasone propionate given separately were effects associated with exaggerated pharmacological actions.
S študijami na živalih z ločenim dajanjem salmeterola in flutikazonpropionata so ugotovili, da edino skrb glede varnosti uporabe pri ljudeh predstavljajo učinki, povezani s pretiranim farmakološkim
• You do not need to shake your inhaler before you use it.
• Inhalatorja pred uporabo ni treba pretresti.
If you are breastfeeding, check with your doctor or pharmacist for advice before taking this medicine.
Če dojite, se posvetujte z zdravnikom ali farmacevtom, preden vzamete to zdravilo.
If your doctor feels that you need a lower dose than is available from your Aerivio Spiromax, your doctor may prescribe an alternative inhaler containing the same active substances as your Aerivio Spiromax but with a lower dose of the corticosteroid.
Če bo zdravnik menil, da potrebujete manjši odmerek, kot je na voljo z zdravilom Aerivio Spiromax, vam lahko predpiše drug inhalator, ki vsebuje enake zdravilne učinkovine kot zdravilo Aerivio Spiromax, toda z manjšim odmerkom kortikosteroida.
There is a linear increase in systemic exposure with increasing inhaled dose.
Sistemska izpostavljenost se linearno povečuje z naraščanjem
Beta blockers are mostly used for high blood pressure or heart conditions such as angina.
Ti se večinoma uporabljajo za zdravljenje visokega krvnega tlaka ali za zdravljenje bolezni srca, kot
This translates to a reduction in the rate of moderate to severe exacerbations of 25% (95% CI: 19% to 31%; p<0.001) compared with placebo, 12% compared with salmeterol (95% CI: 5% to 19%, p=0.002) and 9% compared with FP (95% CI: 1% to 16%, p=0.024).
Preneseno to pomeni zmanjšanje števila zmernih do hudih poslabšanj za 25 % (95-odstotni IZ: 19 % do 31 %; p < 0,001) v primerjavi s placebom, 12 % v primerjavi s salmeterolom (95-odstotni IZ: 5 % do 19 %, p = 0,002) in 9 % v primerjavi s FP (95-odstotni IZ: 1 % do 16 %, p = 0,024).
Aerivio Spiromax should be used correctly in order to achieve effective treatment.
Zdravilo Aerivio Spiromax je treba za učinkovito zdravljenje uporabljati pravilno.
Aerivio Spiromax should be used with caution in patients with severe cardiovascular disorders or heart rhythm abnormalities and in patients with diabetes mellitus, thyrotoxicosis, uncorrected hypokalaemia or patients predisposed to low levels of serum potassium.
Zdravilo Aerivio Spiromax je treba zato uporabljati previdno pri bolnikih, ki imajo hude kardiovaskularne bolezni ali motnje srčnega ritma in pri bolnikih s sladkorno boleznijo, tirotoksikozo, nezdravljeno hipokaliemijo ali predispozicijo za nizke vrednosti serumskega kalija.
The mean number of moderate to severe exacerbations per year was significantly reduced with salmeterol/fluticasone propionate (FP) as compared with treatment with salmeterol, FP and placebo (mean rate in the salmeterol/fluticasone propionate group 0.85 compared with 0.97 in the salmeterol group, 0.93 in the FP group and 1.13 in the placebo).
Povprečno število zmernih do hudih poslabšanj na leto se je značilno zmanjšalo pri salmeterolu/flutikazonpropionatu (FP) v primerjavi z zdravljenjem s salmeterolom, FP in placebom (povprečna vrednost v skupini, ki je prejemala salmeterol/flutikazonpropionat, je bila 0,85 v primerjavi z 0,97 za skupino, ki je prejemala salmeterol, 0,93 za skupino, ki je prejemala FP, in 1,13 za skupino s placebom).
This resulted in a greater reduction of plasma cortisol as compared with fluticasone propionate alone.
Kortizol v plazmi se je zato znižal bolj kot samo s flutikazonpropionatom.
Possible systemic effects include Cushing's syndrome, Cushingoid features, adrenal suppression, decrease in bone mineral density, cataract and glaucoma and more rarely, a range of psychological or behavioural effects including psychomotor hyperactivity, sleep disorders, anxiety, depression or aggression (particularly in children) (see Paediatric population sub-heading below for information on the systemic effects of inhaled corticosteroids in children and adolescents).
Možni sistemski učinki vključujejo Cushingov sindrom, cushingoidne značilnosti, zavrtje delovanja nadledvičnih žlez, zmanjšanje mineralne gostote kosti, katarakto in glavkom, redkeje pa vrsto psiholoških ali vedenjskih učinkov, vključno s psihomotorično hiperaktivnostjo, motnjami spanja, anksioznostjo, depresijo ali agresijo (zlasti pri otrocih) (glejte spodnje podpoglavje Pediatrična populacija za informacije o sistemskih učinkih inhalacijskih kortikosteroidov pri otrocih in mladostnikih).
• Aching, swollen joints and muscle pain.
• boleči, otekli sklepi in bolečine v mišicah;
In addition, if you suddenly stop taking Aerivio Spiromax or reduce your dose of Aerivio Spiromax this may (very rarely) cause you to have problems with your adrenal glands (adrenal insufficiency) which sometimes causes side effects.
Nenadno prenehanje jemanja zdravila Aerivio Spiromax ali zmanjšanje odmerka zdravila Aerivio Spiromax lahko (zelo redko) povzroči tudi težave z nadledvično žlezo (oslabljeno delovanje nadledvične žleze), kar včasih povzroči neželene učinke.
System Organ Class Adverse reaction
Organski sistem Neželeni učinek
Salmeterol/fluticasone propionate 50/500 N = 1533
Salmeterol/flutikazonpropionat 50/500
Presenting symptoms are typically vague and may include anorexia, abdominal pain, weight loss, tiredness, headache, nausea, vomiting, hypotension, decreased level of consciousness, hypoglycaemia, and seizures.
Simptomi, ki se pojavijo, so praviloma nedoločni; med njimi so lahko anoreksija, bolečine v trebuhu, izguba telesne mase, utrujenost, glavobol, navzea, bruhanje, hipotenzija, zmanjšana stopnja zavesti, hipoglikemija in konvulzije.
(*=could not be calculated because of no events in placebo group.
(*=ker se dogodki v skupini, ki je prejemala placebo, niso pojavili, izračun ni možen.
Rare (may affect up to 1 in 1,000 people)
Redki (pojavijo se lahko pri do 1 od 1.000 bolnikov)
Animal studies have shown reproductive toxicity after administration of β2 adrenoreceptor agonists and glucocorticosteroids (see section
Študije na živalih so pokazale škodljiv vpliv na sposobnost razmnoževanja po dajanju agonistov adrenoreceptorjev β2 in glukokortikosteroidov (glejte poglavje 5.3).
Fluticasone propionate given by inhalation at recommended doses has a glucocorticoid anti-inflammatory action within the lungs, resulting in reduced symptoms and exacerbations of asthma, with less adverse effects than when corticosteroids are administered systemically.
V priporočenih odmerkih ima inhalirani flutikazonpropionat v pljučih glukokortikoidno protivnetno delovanje; s tem zmanjša simptome in poslabšanja astme z manj neželenimi učinki, kot so bili opaženi med sistemsko uporabo kortikosteroidov.
Afterwards, rinse your mouth with water and spit it out and/or brush your teeth.
Nato si ustno votlino splaknite z vodo, ki jo izpljunete, in/ali si oščetkajte zobe.